Raj Kurpad, MD
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,066 of the $3,110 with a category attached, or 66.4%. 26 manufacturers reported payments, led by Coloplast at 56.5% of the total. Reporting peaked in 2019 at $1,869 and has fallen 92.9% since, to $133 in 2025. That places this record below the midpoint for urology clinicians in DE, where the typical reported total is $2,396.
Across 102 payments — averaging $30.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$2K
- AbbVie$245
- Astellas Pharma US Inc$157
- Boston Scientific$130
- Neotract Inc.$107
- C. R. Bard, Inc. & Subsidiaries$70
- plus $644 from 20 others
What the payments were for
- Travel & lodging$1,02333%
- Food & beverage$2,06666%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 36 | $1,756 |
| AbbVie | 12 | $245 |
| Astellas Pharma US Inc | 11 | $157 |
| Boston Scientific | 5 | $130 |
| Neotract Inc. | 1 | $107 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $70 |
| Johnson & Johnson | 4 | $66 |
| Rochester Medical Corporation | 2 | $55 |
| Pfizer | 3 | $50 |
| Biocomposites Inc | 1 | $49 |
| Immunitybio, Inc. | 2 | $44 |
| Acerus Pharmaceuticals Corporation | 3 | $43 |
| Baxter Healthcare | 2 | $41 |
| Bayer | 2 | $40 |
| Olympus America Inc. | 2 | $38 |
| Myovant Sciences Inc. | 2 | $30 |
| Verity Pharmaceuticals Inc. | 2 | $28 |
| Urogen Pharma, Inc. | 1 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Hollister Incorporated | 1 | $22 |
| Bioprotect Medical, Inc. | 1 | $21 |
| Abbott | 1 | $18 |
| Urovant Sciences Inc | 1 | $14 |
| AstraZeneca | 1 | $13 |
| Myriad Genetic Laboratories, Inc. | 1 | $13 |
| Blue Earth Diagnostics | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,110 in reported general payments places this provider in the 50th percentile of 33 urology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 70 | $982,963 |
| MyrbetriqMirabegron | 177 | $171,909 |
| OrgovyxRelugolix | 28 | $72,917 |
| Tamsulosin Hcl | 1,012 | $20,539 |
| GemtesaVibegron | 12 | $15,660 |
| Finasteride | 391 | $8,591 |
| ElmironPentosan Polysulfate Sodium | 12 | $7,628 |
| Oxybutynin Chloride ErOxybutynin Chloride | 142 | $4,745 |
| Tolterodine Tartrate ErTolterodine Tartrate | 19 | $2,537 |
| Doxazosin Mesylate | 102 | $2,270 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 13 | $1,971 |
| Silodosin | 15 | $1,896 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 31 | $1,383 |
| Solifenacin Succinate | 35 | $1,048 |
| Oxybutynin Chloride | 32 | $1,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $157 | $1,154,872247 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 33 urology providers in Delaware.
Other urology in Dover
- Joohyong KimDover$7K
- Christopher VallorosiDover$7K
- Michael ZaragozaDover$6K
- Gregory SpanaDover$5K
- Donald SuhDover$2K
- Jason WaltherDover$87
- Christopher MitchellWilmington$19K
- Michael LobisWilmington$8K
- Thomas DesperitoWilmington$7K
- Raymond BolognaMilford$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.